Management of severe hidradenitis suppurativa with biologic therapy and wide excision

Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of late, there has been an increased focus on the use of biologic agents in patients with moderate to severe HS. Here, we present the case of a 46-year-old man with Hurley stage III HS for whom wide excision was ultimately curative, after aggressive medical therapy with the use of infliximab and adalimumab had succeeded in limiting the body surface area affected by the disease. This case demonstrates the effective treatment of severe HS with a combination of biologic therapy and surgery.

Keywords

Hidradenitis suppurativa - Tumor necrosis factor-alpha - Antibodies, monoclonal - Adalimumab - Infliximab

Publication History

Received: 23 March 2018

Accepted: 30 October 2018

Article published online:
28 March 2022

• REFERENCES

• 1 Sellheyer K, Krahl D. “Hidradenitis suppurativa” is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 2005; 44: 535-40
• 2 Zouboulis CC, Desai N, Emtestam L. et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619-44
• 3 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6
• 4 Gulliver W, Zouboulis CC, Prens E. et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord 2016; 17: 343-51
• 5 Kimball AB, Okun MM, Williams DA. et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016; 375: 422-34
• 6 Zouboulis CC, Okun MM, Prens EP. et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol 2019; 80: 60-9
• 7 Grant A, Gonzalez T, Montgomery MO. et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-17
• 8 Kimball AB, Sobell JM, Zouboulis CC. et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol 2016; 30: 989-94
• 9 Blok JL, Li K, Brodmerkel C. et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 2016; 174: 839-46
• 10 Tzanetakou V, Kanni T, Giatrakou S. et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol 2016; 152: 52-9
• 11 Leslie KS, Tripathi SV, Nguyen TV. et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 2014; 70: 243-51
• 12 Houriet C, Seyed Jafari SM, Thomi R. et al. Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases. JAMA Dermatol 2017; 153: 1195-7
• 13 Sun NZ, Ro T, Jolly P. et al. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa. J Clin Aesthet Dermatol 2017; 10: 36-8
• 14 Theut Riis P, Thorlacius LR, Jemec GB. Investigational drugs in clinical trials for hidradenitis suppurativa. Expert Opin Investig Drugs 2018; 27: 43-53
• 15 Ahn CS, Dothard EH, Garner ML. et al. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol 2015; 73: 420-8